-
EP3849963
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3849963
| EP3849963 - DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 18.06.2021 Database last updated on 20.07.2024 | |
| Former | The international publication has been made Status updated on 21.03.2020 | ||
| Former | unknown Status updated on 01.10.2019 | Most recent event Tooltip | 27.09.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states The United States of America, as Represented By the Secretary, Department of Health and Human Services Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard Suite 325 MSC 7660 Bethesda, MD 20892-7660 / US | [2021/29] | Inventor(s) | 01 /
NEWMAN, Amy Hauck National Institutes of Health, OTT 6011 Executive Boulevard, Suite 325 MSC 7660 Bethesda, Maryland 20892-7660 / US | 02 /
KUMAR, Vivek National Institutes of Health, OTT 6011 Executive Boulevard, Suite 325 MSC 7660 Bethesda, Maryland 20892-7660 / US | 03 /
SHAIK, Anver Basha National Institutes of Health, OTT 6011 Executive Boulevard, Suite 325 MSC 7660 Bethesda, Maryland 20892-7660 / US | [2021/29] | Representative(s) | Harris, Oliver John Richard Novagraaf UK Centrum Norwich Research Park Colney Lane Norwich NR4 7UG / GB | [2021/29] | Application number, filing date | 19773300.9 | 09.09.2019 | [2021/29] | WO2019US50165 | Priority number, date | US201862729709P | 11.09.2018 Original published format: US 201862729709 P | [2021/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020055725 | Date: | 19.03.2020 | Language: | EN | [2020/12] | Type: | A1 Application with search report | No.: | EP3849963 | Date: | 21.07.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.03.2020 takes the place of the publication of the European patent application. | [2021/29] | Search report(s) | International search report - published on: | EP | 19.03.2020 | Classification | IPC: | C07D209/30, C07D307/85, C07D317/68, A61K31/40, A61P25/36, C07D471/04, C07D513/04, C07D209/42, C07D233/90, C07D405/12, C07D407/12 | [2021/29] | CPC: |
A61P25/36 (EP,US);
A61K31/496 (US);
A61K31/485 (US);
C07D209/42 (EP);
C07D233/90 (EP);
C07D307/85 (EP);
C07D317/68 (EP);
C07D405/12 (EP);
C07D407/12 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/29] | Title | German: | DOPAMIN-D3 -REZEPTORSELEKTIVE ANTAGONISTEN/PARTIELLE AGONISTEN UND VERWENDUNGEN DAVON | [2021/29] | English: | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | [2021/29] | French: | ANTAGONISTES/AGONISTES PARTIELS SÉLECTIFS DU RÉCEPTEUR D3 DE LA DOPAMINE ET UTILISATIONS ASSOCIÉES | [2021/29] | Entry into regional phase | 11.02.2021 | National basic fee paid | 11.02.2021 | Designation fee(s) paid | 11.02.2021 | Examination fee paid | Examination procedure | 11.02.2021 | Examination requested [2021/29] | 11.02.2021 | Date on which the examining division has become responsible | 30.09.2021 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.09.2021 | Renewal fee patent year 03 | 27.09.2022 | Renewal fee patent year 04 | 27.09.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2008009741 (PF MEDICAMENT [FR], et al); | [XI]WO2017160552 (US HEALTH [US]) |